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Simple Summary: Biomarkers that define breast cancer treatment recommendations include estrogen
receptor (ER), progesterone receptor (PR), and human epidermal growth-factor receptor 2 (HER2);
histological grade; and in many countries, the Ki67 proliferation index. However, the subjective
nature and degree of variability in breast cancer biomarker assessment might result in under- or
overtreatment. We demonstrated that limited variability exists in ER, PR, and HER2 positivity
rates among 29 departments in Sweden, including 43,261 patients. However, even a few outlier
labs affect endocrine and anti-HER2 treatment rates in a clinically relevant proportion, indicating
a need for improvement. Despite international guidelines, standardized protocols, and external
quality control procedures, very high variability was found in Ki67 scoring and histological grading,
indicating a need for new methods. Monitoring rates of biomarker expression and treatments
among departments should be mandatory in order to detect variability issues affecting the clinical
management of breast cancer.
Abstract: We compared estrogen receptor (ER), progesterone receptor (PR), human epidermal growth-
factor receptor 2 (HER2), Ki67, and grade scores among the pathology departments in Sweden. We
investigated how ER and HER2 positivity rates affect the distribution of endocrine and HER2-targeted
treatments among oncology departments. All breast cancer patients diagnosed between 2013 and
2018 in Sweden were identified in the National Quality Register for Breast Cancer. Cases with data on
ER, PR, HER2, Ki67, grade, and treatment were selected (43,261 cases from 29 departments following
the guidelines for biomarker testing). The ER positivity rates ranged from 84.2% to 97.6% with 6/29
labs out of the overall confidence intervals (CIs), while PR rates varied between 64.8% and 86.6%
with 7/29 labs out of the CIs. HER2 positivity rates ranged from 9.4% to 16.3%, with 3/29 labs out of
the overall CIs. Median Ki67 varied between 15% and 30%, where 19/29 labs showed significant
intra-laboratory variability. The proportion of grade-II cases varied between 42.9% and 57.1%, and
13/29 labs were outside of the CI. Adjusting for patient characteristics, the proportion of endocrine
and anti-HER2 treatments followed the rate of ER and HER2 positivity, illustrating the clinical effect
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of inter- and intra-laboratory variability. There was limited variability among departments in ER, PR,
and HER2 testing. However, even a few outlier pathology labs affected endocrine and HER2-targeted
treatment rates in a clinically relevant proportion, suggesting the need for improvement. High
variability was found in grading and Ki67 assessment, illustrating the need for the adoption of new
technologies in practice.
Keywords: positivity rate; biomarker; breast cancer; endocrine treatment; HER2-targeted treat-
ment; variability
1. Introduction
In the era of precision medicine, patient management of invasive breast cancer is
largely based on high-quality tumor biomarker testing. Indeed, breast cancer care has been
a pioneer in the use of molecular features of the tumor to guide clinical decision making.
Beside stage and tumor size, the leading biomarkers that define breast cancer treatment
recommendations are estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth-factor receptor 2 (HER2); histological grade; and in many countries, the
Ki67 proliferation index [1]. Furthermore, ER and HER2 status are strongly predictive for
anti-estrogen therapies [2,3] and HER2-targeted therapies [4,5]. All these biomarkers are
established by the pathological analysis of tumor tissue, which, according to international
guidelines, is mandatory in the analysis of all diagnosed primary breast cancer cases [1]. In
clinical practice, immunohistochemical (IHC) detection is the gold standard for assessing
ER, PR, and Ki67 in routine breast cancer pathology [6,7]. HER2 is analyzed by IHC, and
in equivocal cases by in situ hybridization (ISH) [8]. IHC and ISH methods have several
advantages, including wide applicability and availability with a low cost, ensuring the
assessment of only invasive tumor cells, which may be challenging—especially in small
tumors [9]. However, several studies have demonstrated moderate inter-observer and
inter-laboratory reproducibility in breast cancer biomarker assessment [10,11]. Therefore,
tests with proven analytical and clinical validity as well as clinical utility [12] are critical, as
false-negative tests result in withholding effective treatment, while false-positive tests lead
to overtreatment with costly and ineffective therapy, simultaneously resulting in unwanted
direct and long-term side effects [13,14]. Parameters that predominantly influence the IHC
and ISH results include pre-analytical (type of biopsy, tissue handling), analytical (IHC
and ISH protocol), interpretive, and scoring steps [15]. Standardized procedures should
be used in all steps of biomarker testing. International and national guidelines for the
analysis and interpretation steps have been in place for several years [16]. In addition, to
ensure compliance with validated protocols for testing, it is recommended that laboratories
participate in regular internal and external quality control procedures like UK-NEQAS-
ICC [17] or NordiQC [18]. The quality control work may also include comparisons between
local and central laboratories.
Although external quality control has an important role in maintaining analytical
validity, it cannot be said to represent daily routine, where time-constrained limitation
always applies, and several pathologists perform the diagnostic evaluation. In quality-
control sets it is often the most experienced pathologist with the highest skills in the specific
field who performs the assessment. Furthermore, it is very difficult to compare labs using
different antibodies, detection systems, and protocols. For this reason, the monitoring
of positivity rates has been proposed as a tool to identify laboratories with insufficient
assays and a high yield of false-positive or false-negative results [19,20]. A comparison of
department performances in breast cancer biomarker testing is necessary to ensure that
daily diagnostic practice meets clinical requirements.
In this study we compared the 5-year distribution of ER, PR, and HER2; Ki67 prolifer-
ation index; and histological grade evaluation scores from daily clinical practice among
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pathology departments in Sweden. We also investigated how ER and HER2 positivity rates
affect the use of ER- and HER2-targeted treatments among oncology departments.
2. Materials and Methods
2.1. Data Source and Study Population
We retrieved patient data from NKBC, the Swedish National Quality Register for
Breast Cancer (https://statistik.incanet.se/brostcancer/), which contains detailed clinical
data on patient and tumor characteristics, treatment, and follow-up for all newly diagnosed
primary cases of in situ and invasive breast cancer diagnosed in Sweden since 2008 [21]. The
registry database is considered 99% complete [21]. The reported pathology data contains
biomarker assessment data from the surgical specimen and, if preoperative systemic
treatment, from pre-treatment core needle biopsy [21].
For this study, all invasive breast cancer cases diagnosed between 2013 and 2018
in Sweden were identified, and cases with available data on ER, PR, HER2, Ki67, and
histological grade were selected (n = 43,959). Only pathology departments with more
than 450 diagnosed breast cancer cases in the given period of time were included in the
study, resulting in 43,261 valid cases from 29 investigated departments across Sweden.
In cases with primary surgery, biomarker status was analyzed on the surgical specimen
(n = 38,076), while in cases with neoadjuvant treatment, biomarker status was performed
on the pre-treatment core biopsy (n = 5185). All studied pathology departments follow
the national guidelines of biomarker evaluation [22], and participate in external quality
control, passing breast cancer biomarker runs (Table S1). The distribution of breast cancer
phenotypes across the regions of Sweden is considered homogenous [21]. For each included
case we extracted registry data on patient characteristics (age, date of diagnosis, and date
of surgery) and tumor characteristics (type of tissue specimen, tumor size, histologic grade,
lymph node status, ER, PR, and HER2 status) as well as detailed treatment data. Treatment
data on neoadjuvant and adjuvant endocrine and anti-HER2 therapies were handled as
binary variables (yes or no).
2.2. Biomarker Assessment
According to the Swedish guidelines [22], ER and PR status are considered positive
when ≥10% of tumor cells show ER- and PR-specific staining in tumor nuclei detected by
IHC. Both ER and PR status were taken into account as binary variables, either positive
(≥10%) or negative (<10%). HER2 status was considered either positive or negative, detected
by IHC and/or ISH as recommended by the Swedish guidelines; IHC was performed first,
followed by amplification testing in case of a 2+ IHC score. Between 2013–2018, the Swedish
guidelines were following the 2013 ASCO/CAP guidelines in reporting HER2 status.
The Ki67 proliferation index was analyzed as a continuous variable and defined as
the percentage of tumor cells with positive nuclear staining counted in a hot-spot with a
minimum of 200 tumor cells (in accordance with Swedish guidelines [22]). Histological
grade was performed on hematoxylin and eosin (HE)-stained slides according to the
Nottingham grade scoring system [23]. As intra-tumoral heterogeneity critically affects
histological grade scoring on core biopsy specimens, these were excluded from the study.
2.3. Quality Assurance of Pathology Data Reported to the NKBC
In order to ensure the validity of NKBC data, 8 pathology departments from 3 differ-
ent regions were selected to compare NKBC data with original pathology reports. Two
included breast cancer cases per month at each site were randomly selected for validation
(n = 1076). During part of the studied period, Ki67 was reported as either high or low
(two categories), while more recently this was changed to high, intermediate, or low (three
categories). Therefore, we decided to take into account the reported percentage values only
(Ki67 proliferation index). Validity in biomarker reporting was 95–98.5% and considered
acceptable (relative percentage error rate: 1.5–5%, Table S2).
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2.4. Questionnaire on Analytical Procedures
Since the labs use different antibodies, detection systems, protocols, etc., information
on the analytical factors that might affect the inter-laboratory variation of the biomarkers
was investigated with a questionnaire sent out covering antibody clone, IHC platform, and
protocol used during the studied period. We could not detect any specific analytical factors
causing inter- and intra-laboratory variability (Table S3).
2.5. Statistical Analysis
Separate analysis was performed for ER, PR, HER2, Ki67, histological grade status,
endocrine treatment, HER2-tageted treatment, age, tumor size, and lymph node status as
outcome measures. Kruskal–Wallis test with Dunn’s post-hoc analysis and χ2 tests were
used to compare the departments with one another, resulting in a total of 406 comparisons
per marker. To investigate interannual variability for each department (intra-laboratory
variability), χ2 test was used. We applied Bonferroni correction in multiple comparisons.
To interpret the results, error bars and bar charts with 95% CI levels were used, where
the biomarkers’ rates per department were plotted with the overall national proportion
represented with 95% confidence limits as target. In all statistical analyses, the level of
significance was set at p < 0.05. For statistical analysis, SPSS 25 software was used (IBM,
Armonk, NY, USA).
3. Results
3.1. Patient and Tumor Characteristics
In total, 43,261 patients were included, with biomarker assessment performed at
29 different laboratories. Patient and tumor characteristics for all included cases are listed
in Table 1. The mean age was 63.5 years and the median tumor size was 15 mm. Three out
of four patients were node-negative (72%) based on sentinel-node biopsy and/or axillary
dissection due to the mammography screening introduced over 20 years. More than half
of the tumors were categorized as grade II (51.4%), 87.9% as ER-positive, and 72.8% as
PR-positive. HER2 was considered positive in 13.1%. The median Ki67 proliferation index
was 22%. Endocrine treatment was given to 73.8% of the patients, and HER2-targeted
therapy in 11.6%.
Table 1. Patient and tumor characteristics and treatment in 43,261 cases with biomarker assessment performed at 29
pathology departments.
Variable Category Statistics Results
Patients
Total n, % 43,959 100
Valid n, % 43,261 98.4
Age (years) Mean ± SD 63.5 ± 13.3
Missing data % 0.1 -
Tumor size (mm)
Median, IQR 15 13
Missing data % 1.1 -
Lymph node status
Node-negative %, CI 72.0 71.0–73.0
Node-positive %, CI 28.0 27.0–29.0
Missing data % 2.3 -
Histological grade
(n = 38,076)
Grade I %, CI 21.4 20.0–22.9
Grade II %, CI 51.4 49.9–52.9
Grade III %, CI 27.2 25.5–28.8
Missing data % 1.3 -
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Table 1. Cont.
Variable Category Statistics Results
ER
Positive %, CI 87.9 86.7–89.2
Negative %, CI 12.1 10.8–13.2
Missing data % 4.4
PR
Positive %, CI 72.8 70.9–74.8
Negative %, CI 27.2 25.2–29.1
Missing data % 5.7 -
HER2
Positive %, CI 13.1 12.4–13.8
Negative %, CI 86.9 86.2–87.6
Missing data % 2.3 -
Ki67
Median, IQR 22.0 26
Missing data % 2.0 -
Endocrine treatment
Received %, CI 73.8 71.6-75.9
Not received %, CI 26.2 24.1–28.4
Missing data % 0.7 -
HER2-targeted therapy
Received %, CI 11.6 10.9–12.3
Not received %, CI 88.4 87.7–89.1
Missing data % 0.7 -
CI = 95 % confidence interval; IQR = interquartile range; SD = Standard deviation.
3.2. Variability of ER Positivity Rates and Endocrine Therapy
The distribution of ER-positive cases ranged from 84.2% to 97.6% among the depart-
ments. All 29 labs were compared to each other, encompassing 406 comparisons in total
(inter-lab variability). We found that 88 out of 406 lab comparisons showed significantly
different ER positivity rates, and 5 labs had a positivity rate outside of the overall CI
(Figure 1A). Four labs overvalued, while one lab undervalued the overall CI of ER posi-
tivity rates. Considering intra-laboratory variation in ER scoring, 7 out of 29 labs showed
interannual variation in ER positivity rates (Figure 2A, Figure S1).
We compared the rate of endocrine therapy among the oncology departments, and
found that 179 out of 406 department comparisons were significantly different. Further-
more, 13/29 departments had a rate of endocrine therapy outside of the CI (Figure 1A).
However, we also found statistically significantly different patient characteristics among
departments with regard to age, tumor size, and lymph node status at diagnosis (Figure S2).
Furthermore, there were regional differences in offering endocrine treatment for tumors 10
mm or smaller. Therefore, we applied a case selection including only patients aged 70 or
less and with tumor sizes greater than 10 mm. Adjusting for differences in age and tumor
size among departments, we found that the rate of endocrine therapy strictly followed
that of ER positivity (6 out of 406 department comparisons were statistically significant)
(Figure 1B).
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Figure 1. Endocrine receptor (ER) status and endocrine treatment between 2013 and 2018 by department. Dashed lines
represent the CI for overall positivity (blue) and overall treatment rate (red). (A) includes all the patients while (B) shows
results with cases ≥10 mm T size, ≤70 years of age.
Figure 2. Intra-lab variability for ER (A) and human epidermal growth-factor receptor 2 (HER2) (B) status among pathology
departments. Only laboratories showing statistically significant differences are shown. Please refer to Figure S1 to see all the labs.
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3.3. Variability of PR Positivity Rates
Positivity rates for PR among the departments varied between 64.8% and 86.6%.
Overall, 119 out of 406 lab comparisons were significant, and 7 labs showed positivity
rates outside of the CI (Figure S3). Regarding intra-laboratory variability, 10 out of 29 labs
showed significantly different PR positivity rates between 2013 and 2018 (Figure S3).
3.4. Variability of HER2 Positivity Rates and Anti-HER2 Treatment
The distribution of HER2-positive cases among departments ranged from 9.4% to
16.3%. Regarding inter-lab variability, 14 out of 406 lab comparisons were significantly
different, and two labs overvalued, while one lab undervalued the overall CI of HER2
positivity rates (Figure 3A). Considering intra-laboratory variation in HER2 scoring, 10 out
of 29 labs showed significant interannual variation (Figure 2B, Figure S1).
A comparison of the rate of HER2-targeted treatments among the oncology departments
showed that 19 out of 406 department comparisons were significantly different. Furthermore,
five departments had treatment rates outside of the CI (Figure 3A). Adjusting for differences
in age and tumor size among departments, we found that HER2-targeted therapy strictly
followed that of HER2 positivity, with only one oncology department outside of the overall
CI and 3 out of 406 comparisons statistically significantly different (Figure 3B).
Figure 3. HER2 status and anti-HER2 treatment between 2013 and 2018 by pathology department. Dashed lines represent
the CI for overall positivity (blue) and overall treatment rate (red). (A) includes all the patients while (B) shows results with
cases ≥10 mm T size, ≤70 years of age.
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3.5. Variability of Ki67 Proliferation Index
The median Ki67 proliferation index varied between 15% and 30% among the departments.
Overall, 257 out of 406 lab comparisons were significant (Figure 4A). Regarding intra-laboratory
variability, 19 out of 29 labs showed significant interannual variation (Figure 4B).
Figure 4. Inter- (A) and intra-laboratory variability (B) for Ki67 among 29 pathology departments.
3.6. Variability of Histological Grade
The proportion of histological grade II cases among the departments ranged from
42.9% to 57.1%. Of 406 lab comparisons, 104 were significantly different, and 13 labs had a
distribution rate outside of the overall CI (Figure 5A). When considering histological grade
as a binarized variable, similar inter-lab variability was seen (93 out of 406 lab comparisons
with p < 0.05). Considering intra-laboratory variation, 15 out of 29 labs showed significant
interannual variation (Figure 5B).
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Figure 5. Inter- (A) and intra-laboratory variability (B) for histological grade status among 29 pathology departments.
4. Discussion
We investigated inter- and intra-laboratory variability in the assessment of ER, PR,
HER2, Ki67, and histological grade in a non-selective population-based nationwide cohort
of 43,261 invasive breast cancer patients diagnosed between 2013 and 2018, using real-world
data from the Swedish National Quality Register for Breast Cancer (NKBC). The patients
involved in this study represent 98.4% of breast cancer cases occurring between 2013 and
2018 in Sweden. We demonstrated that there was limited variability in ER, PR, and HER2
positivity rates among pathology departments. Overall positivity rates were 87.9% for ER,
72.8% for PR, and 13.1% for HER2, with a median Ki67 proliferation index of 22% and
51.4% of tumors deemed grade II, which are in line with international findings [19,20,24–30].
Although the proportion HER2 positivity ranged from 9.4% to 16.3% (thus varying from
1 positive out of 6 tested patients to 1 positive out of 11 patients tested), the confidence
intervals were broadly overlapping for the vast majority of the labs. The same observation
applies for positivity rates of ER and PR among the pathology departments. A recent
investigation involving 33,046 patients performed in the Netherlands using a similar study
design showed comparable variability among pathology departments in ER, PR, and HER2
positivity rates [25]. Other studies have shown significant variation among pathology
laboratories, with HER2 positivity rates varying from 7.6% to 31.6% [19,20] and with
significant outliers even after adjusting for population characteristics [20]. Moreover, our
results demonstrate that when adjusting for clinicopathological factors, the distribution
of endocrine therapy and HER2-targeted treatments strictly followed the differences of
ER and HER2 positivity rates among pathology departments, leading to the same relative
difference in drug prescription rates among oncology departments.
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To the best of our knowledge, this is the first study to investigate the association
between positivity rates of ER and HER2 among pathology laboratories and the distribution
of endocrine therapy and HER2-targeted treatments among oncology departments.
Although the number of outlying departments is limited (ER: 6/29; PR: 7/29; HER2:
3/29), the slightly higher rate of intra-laboratory variability shows that there is still room for
improvement—especially because such variation will be directly translated into treatment
decisions. Stage, grade, and biomarker assessment are pillars for the multidisciplinary
recommendations regarding surgery, chemotherapy, endocrine, and targeted therapies.
Valid analyses with low variability could potentially improve patient outcomes.
Two previous studies investigated reproducibility in routine breast cancer bio-marker
assessment at Swedish pathology departments. In the first study, a tissue microarray of
11 breast cancers to stain and evaluate for HER2 status was sent out twice to 24 depart-
ments [31]. The authors demonstrated a very good reproducibility in this round robin study,
and showed a good analytical variability. However, the study did not reflect daily diagnos-
tic routine [31]. In the second study, 10 cases from each of 27 participating departments
were systematically collected and sent to a reference lab for re-staining and re-scoring of ER,
PR, HER2, and Ki67 [32]. Although the authors demonstrated a very good agreement and
observed discrepancies seemed to be explained by analytical differences, the study design
did not enable comparison of individual departments [32]. In the present study, limited
variability regarding ER, PR, and HER testing was found, which is in accordance with
previous studies. On the other hand, we also demonstrated unacceptable inter- and intra-
laboratory variability in histological grade and Ki67 assessment, urging imminent efforts to
further standardize testing procedures. In a large study of 33,043 non-selected breast cancer
patients, van Dooijeweert et al. also demonstrated a substantial variability in histological
grading among pathology departments [29]. It has long been acknowledged that both Ki67
and histological grade provide useful prognostic information [30,33,34]. However, they are
subject to reproducibility issues which diminish clinical utility [11,35,36]. According to the
Swedish guidelines, all ER-positive breast cancer patients are categorized into luminal-A-
like and luminal-B-like subtypes based on tumor histological grade, Ki67, and PR status.
All grade I and grade III cases are categorized as luminal-A-like and luminal-B-like, respec-
tively. Grade II cases with low and high Ki67 values (based on local cut-offs) are divided
into luminal-A-like and luminal-B-like, respectively. Grade II cases with intermediate Ki67
score are further measured by PR status in order to being divided into luminal-A-like
(PR expression ≥20%) and luminal-B-like (PR expression <20%) subtypes [37]. As both
histological grade and Ki67 status play important roles in the prognostication of breast
cancer patients, the high variability found between pathology departments regarding these
markers has serious clinical implications. Although significant efforts have been made to
standardize pathologist-read scoring for these markers [38], introducing new methods to
this field such as digital-image analysis and molecular methods would hold the promise of
increasing reproducibility [39–43]. Besides, we believe that Ki67 IHC and its evaluation
should undergo rigorous external quality-control procedures (similarly to ER, PR, and
HER2), which is not currently the case. Furthermore, the new International Ki67 in Breast
Cancer Working Group recommendations have been established, providing specific and
detailed guidelines for each step of Ki67 assessment with the levels of evidence for its
technical validity and clinical utility as a biomarker [44]. Following these guidelines in
clinical practice has the potential to reach an acceptable reproducibility for Ki67 assessment.
There are several potential limitations to this study. First of all, as the proportion
of neoadjuvant treatment differs among oncology departments, the proportion of cases
analyzed based on pretreatment biopsy instead of surgical specimen differ. Tumor hetero-
geneity might affect the concordance in biomarker expression rates between core biopsy
sample and resection specimen. However, several studies have demonstrated good agree-
ment in biomarkers between core biopsy sample and resection specimen, especially for
ER [45–47]. However, this does not apply to histological grade, as only a small tumor
area is presented in the biopsy specimen. For this reason, we excluded all grade scores
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reported based on core biopsy specimens only. Additionally, although the distribution of
breast cancer molecular phenotypes seems to be homogenous between regions in Sweden,
some differences in case-mix may remain despite adjustments for age and stage among
different departments. Furthermore, the study design did not enable us to control the
pre-analytical and analytical factors, potentially affecting assessments. For this reason, a
questionnaire regarding used antibodies, IHC platforms, and protocols was sent out, and
results from the NordiQC were retrieved to make sure that all participating departments
had previously passed analytical validity testing. As IHC and ISH staining needs to be run
overnight in practice, we hypothesized that the definitive biomarkers status might have
been added to the pathology report afterward, and thus be missing in the report to NKBC.
However, we found low rates of missing data, and it equally affected receptor-positive and
receptor-negative tumors.
5. Conclusions
We demonstrated in a nation-wide population-based cohort study that there is limited
variability in ER, PR, and HER2 testing among laboratories. However, as even a few outlier
pathology labs affected endocrine and anti-HER2 treatment rates in a clinically relevant
proportion, our study results indicate a need for further improvement. Despite inter-
national and national guidelines for analysis and interpretation, standardized protocols,
and previous internal and external quality control procedures, very high variability was
found in Ki67 scoring and histological grading, which suggests a need for the use of new
methods. Monitoring and comparing rates of biomarker expression and treatments among
departments should be mandatory in order to detect variability issues affecting the clinical
management of breast cancer.
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